Oncolytics Biotech (NASDAQ:ONCY) Price Target Cut to $3.00 by Analysts at Maxim Group

Oncolytics Biotech (NASDAQ:ONCY) had its target price decreased by Maxim Group from $5.00 to $3.00 in a research note published on Monday morning,Benzinga reports. Maxim Group currently has a buy rating on the stock.

ONCY has been the subject of several other research reports. Royal Bank of Canada decreased their price objective on shares of Oncolytics Biotech from $6.00 to $5.00 and set an “outperform” rating for the company in a research note on Monday. Leede Financial downgraded shares of Oncolytics Biotech from a “strong-buy” rating to a “moderate buy” rating in a research note on Wednesday, November 13th. HC Wainwright reissued a “buy” rating and set a $5.00 price objective on shares of Oncolytics Biotech in a report on Monday. Finally, Raymond James raised shares of Oncolytics Biotech to a “moderate buy” rating in a report on Thursday, November 14th. Three investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Oncolytics Biotech presently has an average rating of “Buy” and a consensus price target of $4.00.

Oncolytics Biotech Trading Down 6.8 %

Shares of NASDAQ:ONCY opened at $0.64 on Monday. Oncolytics Biotech has a 12 month low of $0.60 and a 12 month high of $1.53. The company has a 50-day moving average price of $0.78 and a 200 day moving average price of $0.93. The company has a market cap of $54.89 million, a price-to-earnings ratio of -2.38 and a beta of 1.18.

Institutional Investors Weigh In On Oncolytics Biotech

Large investors have recently made changes to their positions in the stock. Vantage Point Financial LLC acquired a new position in shares of Oncolytics Biotech in the fourth quarter worth about $27,000. National Bank of Canada FI grew its stake in Oncolytics Biotech by 199.6% during the 4th quarter. National Bank of Canada FI now owns 64,479 shares of the company’s stock valued at $60,000 after acquiring an additional 42,955 shares in the last quarter. Geode Capital Management LLC grew its stake in Oncolytics Biotech by 59.6% during the 4th quarter. Geode Capital Management LLC now owns 66,939 shares of the company’s stock valued at $61,000 after acquiring an additional 24,997 shares in the last quarter. Virtu Financial LLC purchased a new stake in Oncolytics Biotech during the 4th quarter valued at about $90,000. Finally, International Assets Investment Management LLC grew its stake in shares of Oncolytics Biotech by 15.0% in the 4th quarter. International Assets Investment Management LLC now owns 200,400 shares of the company’s stock valued at $186,000 after buying an additional 26,069 shares during the period. 6.82% of the stock is owned by hedge funds and other institutional investors.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.